Helping a multinational pharmaceutical company expand its business to new markets
A multinational pharmaceutical company wanted to accelerate growth beyond current strategic focus areas and mitigate a projected launch gap by acquiring promising drug candidates. Arthur D. Little was asked to help the client screen for advanced stage development compounds outside of the client’s current disease area footprint that might be attractive and innovative assets to target.
White Space Selection Process
Together with the client the scope of diseases to include was set and based on the scope the project was conducted in four phases using a funnel approach combining desk research and intensive interaction with Arthur D. Little’s expert network:
- Search for candidates through desk and database research and define inclusion and exclusion criteria
- Evaluation of candidates in five dimensions to understand the availability of the compound as well as the attractiveness of related therapeutic markets in terms of competition, medical need, and commercial potential in order to prioritize candidates and create a longlist
- Deep-dive in selected areas, including pharmacology, probability of success in efficacy studies, scientific quality and regulatory aspects
- Project plan consolidation
Attractive and Suitable Acquisition Targets
The evaluation resulted in a comprehensive profile of 11 attractive and suitable White Space candidates out of an initial list of more than 2,500. The project ensured that the most strategically attractive indications were chosen. The project further opened up doors to unexploited markets and identified the best candidates to give our client a leading position.